Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
91
NBTX Quote, Financials, Valuation and Earnings
Last price:
$32.14
Seasonality move
:
4.43%
Day range:
$28.18 - $31.62
52-week range:
$2.95 - $31.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
43.30x
P/B ratio:
--
Volume:
86.1K
Avg. volume:
24.2K
1-year change:
786.86%
Market cap:
$1.5B
Revenue:
-$12.6M
EPS (TTM):
-$0.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBTX
Nanobiotix SA
|
-- | -- | -- | -- | $27.74 |
|
CLLS
Cellectis SA
|
$12.7M | -$0.11 | 24.25% | -56.58% | $7.25 |
|
DBVT
DBV Technologies SA
|
$1.2M | -$0.23 | -- | -86.12% | $40.02 |
|
GNFTF
Genfit SA
|
$33.6M | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -- | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBTX
Nanobiotix SA
|
$31.04 | $27.74 | $1.5B | -- | $0.00 | 0% | 43.30x |
|
CLLS
Cellectis SA
|
$3.88 | $7.25 | $390.3M | -- | $0.00 | 0% | 4.83x |
|
DBVT
DBV Technologies SA
|
$20.99 | $40.02 | $1.2B | -- | $0.00 | 0% | -- |
|
GNFTF
Genfit SA
|
$10.50 | -- | $525.4M | 49.25x | $0.00 | 0% | 11.55x |
|
NICXF
Nicox SA
|
$0.30 | -- | $24.3M | -- | $0.00 | 0% | 5.89x |
|
TRGNF
Transgene SA
|
$1.00 | -- | $132.3M | -- | $0.00 | 0% | 1,122.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBTX
Nanobiotix SA
|
195.9% | 3.448 | 20.12% | 1.38x |
|
CLLS
Cellectis SA
|
54.27% | -0.262 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.983 | 5.85% | 1.41x |
|
GNFTF
Genfit SA
|
-- | -1.901 | -- | -- |
|
NICXF
Nicox SA
|
54.24% | 0.872 | 91.41% | 1.21x |
|
TRGNF
Transgene SA
|
-- | 0.550 | -- | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBTX
Nanobiotix SA
|
-- | -- | -161.14% | -- | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
GNFTF
Genfit SA
|
-- | -- | -- | -- | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -24.01% | -43.13% | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -182.92% | -182.92% | -- | -- |
Nanobiotix SA vs. Competitors
-
Which has Higher Returns NBTX or CLLS?
Cellectis SA has a net margin of -- compared to Nanobiotix SA's net margin of 1.68%. Nanobiotix SA's return on equity of -- beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital NBTXNanobiotix SA-- -- $24.3M CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About NBTX or CLLS?
Nanobiotix SA has a consensus price target of $27.74, signalling downside risk potential of -10.62%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 86.86%. Given that Cellectis SA has higher upside potential than Nanobiotix SA, analysts believe Cellectis SA is more attractive than Nanobiotix SA.
Company Buy Ratings Hold Ratings Sell Ratings NBTXNanobiotix SA6 0 0 CLLSCellectis SA2 2 0 -
Is NBTX or CLLS More Risky?
Nanobiotix SA has a beta of 0.626, which suggesting that the stock is 37.373% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.855, suggesting its more volatile than the S&P 500 by 185.46%.
-
Which is a Better Dividend Stock NBTX or CLLS?
Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBTX or CLLS?
Nanobiotix SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. Nanobiotix SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 43.30x versus 4.83x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBTXNanobiotix SA43.30x -- -- -- CLLSCellectis SA4.83x -- $35M $586.4K
-
Which has Higher Returns NBTX or DBVT?
DBV Technologies SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital NBTXNanobiotix SA-- -- $24.3M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About NBTX or DBVT?
Nanobiotix SA has a consensus price target of $27.74, signalling downside risk potential of -10.62%. On the other hand DBV Technologies SA has an analysts' consensus of $40.02 which suggests that it could grow by 90.89%. Given that DBV Technologies SA has higher upside potential than Nanobiotix SA, analysts believe DBV Technologies SA is more attractive than Nanobiotix SA.
Company Buy Ratings Hold Ratings Sell Ratings NBTXNanobiotix SA6 0 0 DBVTDBV Technologies SA4 0 1 -
Is NBTX or DBVT More Risky?
Nanobiotix SA has a beta of 0.626, which suggesting that the stock is 37.373% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.975, suggesting its less volatile than the S&P 500 by 197.455%.
-
Which is a Better Dividend Stock NBTX or DBVT?
Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBTX or DBVT?
Nanobiotix SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 43.30x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBTXNanobiotix SA43.30x -- -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns NBTX or GNFTF?
Genfit SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Genfit SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBTXNanobiotix SA-- -- $24.3M GNFTFGenfit SA-- -- -- -
What do Analysts Say About NBTX or GNFTF?
Nanobiotix SA has a consensus price target of $27.74, signalling downside risk potential of -10.62%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Nanobiotix SA has higher upside potential than Genfit SA, analysts believe Nanobiotix SA is more attractive than Genfit SA.
Company Buy Ratings Hold Ratings Sell Ratings NBTXNanobiotix SA6 0 0 GNFTFGenfit SA0 0 0 -
Is NBTX or GNFTF More Risky?
Nanobiotix SA has a beta of 0.626, which suggesting that the stock is 37.373% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 99.966%.
-
Which is a Better Dividend Stock NBTX or GNFTF?
Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBTX or GNFTF?
Nanobiotix SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Genfit SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 49.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 43.30x versus 11.55x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBTXNanobiotix SA43.30x -- -- -- GNFTFGenfit SA11.55x 49.25x -- --
-
Which has Higher Returns NBTX or NICXF?
Nicox SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Nicox SA's return on equity of -43.13%.
Company Gross Margin Earnings Per Share Invested Capital NBTXNanobiotix SA-- -- $24.3M NICXFNicox SA-- -- $46.8M -
What do Analysts Say About NBTX or NICXF?
Nanobiotix SA has a consensus price target of $27.74, signalling downside risk potential of -10.62%. On the other hand Nicox SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Nanobiotix SA has higher upside potential than Nicox SA, analysts believe Nanobiotix SA is more attractive than Nicox SA.
Company Buy Ratings Hold Ratings Sell Ratings NBTXNanobiotix SA6 0 0 NICXFNicox SA0 0 0 -
Is NBTX or NICXF More Risky?
Nanobiotix SA has a beta of 0.626, which suggesting that the stock is 37.373% less volatile than S&P 500. In comparison Nicox SA has a beta of -0.051, suggesting its less volatile than the S&P 500 by 105.13%.
-
Which is a Better Dividend Stock NBTX or NICXF?
Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nicox SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Nicox SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBTX or NICXF?
Nanobiotix SA quarterly revenues are --, which are smaller than Nicox SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Nicox SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Nicox SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 43.30x versus 5.89x for Nicox SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBTXNanobiotix SA43.30x -- -- -- NICXFNicox SA5.89x -- -- --
-
Which has Higher Returns NBTX or TRGNF?
Transgene SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Transgene SA's return on equity of -182.92%.
Company Gross Margin Earnings Per Share Invested Capital NBTXNanobiotix SA-- -- $24.3M TRGNFTransgene SA-- -- -$660.3K -
What do Analysts Say About NBTX or TRGNF?
Nanobiotix SA has a consensus price target of $27.74, signalling downside risk potential of -10.62%. On the other hand Transgene SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Nanobiotix SA has higher upside potential than Transgene SA, analysts believe Nanobiotix SA is more attractive than Transgene SA.
Company Buy Ratings Hold Ratings Sell Ratings NBTXNanobiotix SA6 0 0 TRGNFTransgene SA0 0 0 -
Is NBTX or TRGNF More Risky?
Nanobiotix SA has a beta of 0.626, which suggesting that the stock is 37.373% less volatile than S&P 500. In comparison Transgene SA has a beta of 43.826, suggesting its more volatile than the S&P 500 by 4282.564%.
-
Which is a Better Dividend Stock NBTX or TRGNF?
Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Transgene SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Transgene SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBTX or TRGNF?
Nanobiotix SA quarterly revenues are --, which are smaller than Transgene SA quarterly revenues of $105.2K. Nanobiotix SA's net income of -- is lower than Transgene SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Transgene SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 43.30x versus 1,122.44x for Transgene SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBTXNanobiotix SA43.30x -- -- -- TRGNFTransgene SA1,122.44x -- $105.2K --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
